Loading...
•
Mar 31, 2023
Compass Q1 2023 Earnings Report
Reported first quarter financial results.
Key Takeaways
Compass Therapeutics reported a net loss of $7.8 million for the first quarter of 2023. The company's cash and marketable securities were $175 million as of March 31, 2023, providing an anticipated cash runway into 2026.
Net loss for the quarter ended March 31, 2023, was $7.8 million or $0.06 per share.
Cash and marketable securities were $175 million as of March 31, 2023.
The company used $12 million of cash to fund operations during the first quarter of 2023.
R&D expenses were $6.6 million for the first quarter ended March 31, 2023.